Aggressive versus indolent insulinomas – new clinicopathological insights

in Endocrine-Related Cancer
Authors:
Wenzel M. HackengW Hackeng, Pathology, University Medical Centre Utrecht, Utrecht, Netherlands

Search for other papers by Wenzel M. Hackeng in
Current site
Google Scholar
PubMed
Close
,
Lodewijk A.a. BrosensL Brosens, Pathology, University Medical Centre Utrecht, Utrecht, Netherlands

Search for other papers by Lodewijk A.a. Brosens in
Current site
Google Scholar
PubMed
Close
, and
Koen M.a. DreijerinkK Dreijerink, Internal Medicine and Endocrinology, Amsterdam University Medical Centers, location VU University Medical Center, Amsterdam, Netherlands

Search for other papers by Koen M.a. Dreijerink in
Current site
Google Scholar
PubMed
Close
View More View Less

Correspondence: Wenzel Hackeng, Email: wenzelhackeng@gmail.com
Restricted access

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $1.00
USD  $1.00

USD  $1.00
USD  $1.00

Insulinomas are rare functional pancreatic neuroendocrine tumors. While most insulinomas are indolent and cured after surgery, 10-15% of cases show aggressive or malignant tumor behavior and metastasize locally or to distant organs. Patients with metastatic insulinoma survive significantly shorter. Recognizing aggressive insulinomas can help to predict prognosis, guide therapy and determine follow-up intensity after surgery. This review offers a summary of the literature on the significant clinical, pathological, genetic and epigenetic differences between indolent and aggressive insulinomas. Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, expression of ARX and alpha-1-antitrypsin; and decreased or absent immunohistochemical expression of insulin, PDX1 and GLP-1R. Moreover, aggressive insulinomas often harbor ATRX or DAXX mutations, the alternative lengthening of telomeres phenotype (ALT) and chromosomal instability (CIN). Tumor grade and MEN1 and YY1 mutations are less useful for predicting behavior. Aggressive insulinomas have similarities to normal alpha-cells and non-functional pancreatic neuroendocrine tumors, while indolent insulinomas remain closely related to normal beta-cells. In conclusion, indolent and aggressive insulinoma are different entities, and distinguishing these will have future clinical value in determining prognosis and treatment.

 

  • Collapse
  • Expand